Introduction
Obesity is a common characteristic of type 2 diabetes, and is also a major contributing factor to insulin resistance, a hallmark feature of type 2 diabetes. Insulin resistance, defined as a decreased ability of target tissues and organs such as fat, skeletal muscle and liver to respond normally to insulin, most often precedes the overt diabetes by many years and is the best predictor of whether or not an individual will become diabetic [1, 2] . Although there are genetic factors that contribute to insulin resistance, insulin resistance is also induced by acquired factors such as obesity, sedentary life style and hormone excess. Consumption of high-calories diets is considered to be one of the main environmental triggers [3] . Insulin resistance is manifested by decreased insulin-stimulated glucose transport and metabolism in adipocytes/skeletal muscle and by impaired suppression of hepatic glucose production in liver. At the molecular level, insulin resistance correlates with impaired insulin signaling in insulin-sensitive tissues. However, the definite mechanisms responsible for insulin resistance have not yet been elucidated.
Oxidative stress, defined as a serious imbalance between the production of reactive species and antioxidant defenses leading to potential tissue damage, has been implicated in the pathogenisis of insulin resistance [4] . There is considerable evidence that hyperglycemia and dyslipidaemia in obesity can result in the generation of reactive oxygen species (ROS), subsequently leading to increased oxidative stress in a variety of tissues. One major consequence of oxidative stress is defective insulin signaling and/or impaired insulin secretion, which will be ultimately responsible for the onset of insulin resistance and the late complications of diabetes.
Melatonin (N-Acetyl-5-methoxytryptamine), the main product secreted by pineal gland, is involved in a variety of important biological activities ranging from the regulation of biological clock to serving as free radical scavenger and antioxidant. Besides direct scavenging actions, melatonin augments the activities of several antioxidative enzymes including superoxide dismutase (SOD), glutathione peroxidase (GPx), and glutathione reductase (GRx), thus lowering the oxidative state of cells [5] [6] [7] [8] . Numerous in vitro and in vivo studies have documented the ability of both physiological and pharmacological concentrations of melatonin to protect against free radical destruction. Furthermore, beneficial antioxidant effects of melatonin have been recently shown in clinical settings for several chronic diseases, including patients with rheumatoid arthritis [9] , elderly patients with primary essential hypertension [10] , and females with infertility [11] . Melatonin is also an effective agent for the treatment of acute stroke [12] . However, the studies which investigate the effect of melatonin on obesity, insulin resistance, and type 2 diabetes are relatively few.
There is increasing interest in strategies to prevent the progression of insulin resistance and obesity to type 2 diabetes. Several clinical trials have demonstrated improved insulin sensitivity in insulin-resistant and/or diabetic patients treated with the antioxidants vitamin C, a-lipoic acid, vitamin E, and glutathione [13] [14] [15] [16] . Recent in vivo study in animal models of diabetes indicated protective effects of melatonin against oxidative stress induced by streptozotocin [17] . In addition long-term melatonin administration also improves lipid metabolism in type 2 diabetic rats, probably through restored insulin resistance [18] . In this study, we sought to determine whether melatonin is also efficacious in preventing lipid-induced insulin resistance in rats, with particular reference to its possible effects on the intrahepatic insulin signaling cascade. Our results indicated that melatonin possesses the protective effects in HFD rats.
Experimental Procedures

Reagents
Melatonin (from Sigma Inc.) was dissolved in ethanol, then diluted in saline with the final ethanol concentration 1%. Antibodies(monoclonal antibody or polyclonal antibody) against phospho-JNK (Thr183/Tyr185), JNK, phospho-IRS2(Tyr612), IRS2, phospho-PKB (Ser473), PKB were all purchased from Cell Signaling Inc. Antibodies against β-actin, human recombinant insulin were obtained from Santa Cruz Biotechnology, Inc.
NBT/BCIP(Nitro-Blue-Tetrazolium/5-bromo-4-chloro-3-indolyl-phosphate) was purchased from AMRESCO Inc.(USA). Bicinchoninic acid (BCA) protein detection kit and other chemicals were obtained from Beijing Zhongshan Biotechnology Co. (P. R. China).
Animal maintenance and treatment
Twenty four male Sprague-Dawley rats (150-200 g) were obtained from Disease Preventing Center of Hubei Province, China. Animals were housed two per cage and given free access to water and a standard laboratory diet or high fat diet. The macronutrient composition of the diets expressed as a percentage of total dietary calories was as follows: standard diet: 18% fat, 33% protein, and 48% carbohydrate; high-fat diet: 59% fat, 21% protein, and 20% carbohydrate. All rats were subjected to alternate 12-h periods of dark and light (lights on 6:00 a.m.-6:00 p.m.). Temperature and humidity were maintained at 23°C and 40-60%, respectively. Rats were randomly assigned to three groups: (1) control group (n=8), fed with standard chow; (2) high-fat group (HF group, n=8), fed with high fat diet (3) HF+MT group, n=8, fed with highfat diet and supplement with 5 mg kg -1 d -1 melatonin i.p. During the feeding period, every group was injected intraperitoneally with melatonin (5 mg kg -1 ) or vehicle (equal amount of saline including 1% ethanol). These treatments were administered for 10 weeks daily at 8:00 p.m. Rats were weighed weekly. At the end of the treatment period, oral glucose tolerance test (OGTT) was carried out after an overnight fasting. Rats were injected i.p. with insulin (5 U kg -1 ) and decapitated. Blood samples were collected for further analysis. The liver tissues were removed and frozen in liquid nitrogen. Retroperitoneal, mesenteric, and epiploon fat were dissected and immediately weighed to calculate the fat weight and body weight ratio (FW/BW). All procedures were performed under an institutionally approved protocol in accord with the NIH Guide for Care and Use of Laboratory Animals. All protocols were approved by the local Animal Ethics Committee. 
Measurement of plasma parameters
Oral glucose tolerance test (OGTT), insulin sensitivity index (ISI) and insulin resistance analysis (HOMA-IR)
After an overnight fast, rats were performed a glucose tolerance test with glucose (2 g kg -1 , 10% solution) intragastrically. Blood samples were collected at 0, 30, 60, 90 and 120 min. Glucose concentration was immediately determined. Fasting insulin level was measured prior to OGTT. Fasting blood glucose (FBG) and fasting insulin (FINS) were calculated for insulin sensitivity index (ISI). ISI=ln1/(FBG×FINS). Insulin resistance degree was determined with the homeostasis model assessment of insulin resistance (HOMA-IR). HOMA-IR = FBG×FINS/22.5.
Western blot analysis
The liver tissues were homogenized in lysis buffer. After lysate preparation, proteins (20-40 g) were separated on 10% SDS-PAGE, transferred onto PVDF membranes, and blocked with 5% nonfat milk-TBS/0.05% Tween (TBST) for 1 h. Blots were probed with primary antibodies against phospho-JNK (Thr183/Tyr185), JNK, phospho-IRS2(Tyr612), IRS2, phospho-PKB(Ser473), PKB. Secondary antibodies were affinity-purified goat antibodies against rabbit or mouse immunoglobulins conjugated with alkaline phosphatase (ALP) (Bio-Rad Laboratories, Inc.). β-actin served as loading control. Specific protein bands were detected by NBT/BCIP reaction, followed by quantitative analysis of the intensity of the bands by NIH-Image software.
Measurement of phosphoenolpyruvate carboxykinase (PEPCK) activity
About 0.05 g of frozen liver was pulverized under liquid nitrogen, homogenized in 1ml of Buffer (pH 7.4) containing 250 mmo/L sucrose, 10 mmol/L HEPES for 20 s, and centrifuged at 100,000xg (4°C) for 30 minutes twice. Proteins were quantified using Coomassie brilliant blue methods. PEPCK activity was measured in cytosolic supernatants by the decarboxylation assay described by Jomain-Baum and Schramm [19] . Ten microliter of cytosolic supernatants were added in the reaction system of 1ml final volum (50 mmol/L Tris-HCL, 0.75 mmol/L MnCl 2 , 1 mmol/L NAD + , 1 mmol/L GTP, 6 U malate dehydrogenase, pH 7.4). Reactions were started by 10 mmol/L malate, and PEPCK activity determined NADH formation at 37°C. A reaction blank was obtained without malate.
RT-PCR
Primers were purchased from Sangon Biological Technology Company (Shanghai, China). Total RNA was extracted from liver tissues using Trizol reagent as manufacturer's instruction (Invitrogen, Life Technologies), and its quantity and quality were detected on a spectrophotometer. The reaction mix (about 1 µg of denatured and Purified RNA, 20 units
pmol/L of primer Oligo (dT) 15 , 20 units of MMLV, 0.5 mmol/L dNTP, 5×reaction buffer to a final volume of 20 ul with RNase-free water) were incubated at 37°C for 1h for reverse transcription. Four microliter of RT product was used as template. The primers were: PEPCK, 328 bp, forward:
b-actin, 480 bp, forward: 5'-CATCCTGCGTCTGGACCT-3', reverse: 5'-TCAGGAGGAGCAATGATCTTG-3'. Four microliter of RT product was mixed with 400 nmol/L forward primer, 400 nmol/L reverse primer, 0.2 mmol/L dNTP, 2.5 units of Taq DNA polymerase, 10×reaction buffer, 3.0 μl of 25 mmol/L MgCl 2 (but 1.5 μl for β-actin gene), to a final volume of 50 ul with RNase-free water. After an initial denaturation at 94°C for 5 min, Amplification was performed with denaturation at 94°C for 60 s, annealing at 60°C for 60 s, and extension at 72°C for 90 s for 30 cycles, followed by at 72°C for 10 min. Ten microliter of PCR products were analyzed by agarose gel electrophoresis (15 g/L) and visualized by ethidium bromide staining and ultraviolet illumination. Expression of PEPCK and β-actin were scanned by Champ Gel Image Analysis System (Beijing Page Creation Science Company, Beijing, China). The obtained values were related to housekeeping gene β-actin, and the resulting relative ratios were analyzed statistically.
Statistical analysis
Data were analyzed with SPSS 11.5 software. Quantitative data were presented as mean ±S.D. and compared using one way ANOVA procedure followed by Dunnet's post hoc comparisons. Differences were considered statistically significant at P<0.05.
Results
Effects of melatonin on body weight (BW) and abdominal fat weight/body weight (FW/BW)
HFD rats were significantly heavier than the normal control rats (approximately 20% heavier compared to controls). However, melatonin administration to those HFD rats resulted in a reverse trend of weight gain. BW was significantly lower in the HF+MT group than that in the HF group (P<0.05; Table 1 ). The FW/BW of rats in HF group was higher than that in the normal and HF+MT groups (P<0.05; Table 1 ), which indicated melatonin could decrease BW and abdominal fat accumulation in HFD rats. 
Effects of melatonin on metabolic profiles
Effects of melatonin on glucose homeostasis, insulin sensitivity, insulin resistance state
To further characterize the effects of melatonin on whole-body glucose homeostasis and insulin resistance state, we performed the OGTT after treatment of HFD rats with melatonin for 10 weeks. In addition, insulin sensitivity index (ISI) and HOMA index (the homeostasis model assessment of insulin resistance, HOMA-IR) were calculated. Rats from the HF group showed marked glucose intolerance and insulin resistance compared with those from both normal and melatonin treatment groups (Table 2) . Melatonin also significantly improved glucose tolerance in HFD rats, because during OGTT the plasma glucose concentration was lower at each time point in HF+MT group than that in HF group (P<0.05, Figure 1) . Furthermore, Melatonin-treated rats had higher ISI (a marker of insulin sensitivity), and lower HOMA index (a marker of insulin resistance) than HDF rats ( Table 2 ). The data suggested that melatonin could improve glucose homeostasis and insulin resistance in high-fat induced obese rats.
Effects of melatonin on oxidative stressrelated parameters
Hepatic and plasma oxidative stress markers were evaluated by changes in the amount of lipid peroxides, measured as MDA and SOD activity in plasma and homogenates of hepatic tissue. Table 3 shows the level of MDA and activity of SOD in plasma and liver in three groups. HFD rats had a significant increase in MDA level and a decrease in SOD activity compared to control rats both in plasma and in liver (P<0.05). However, administration of melatonin markedly reversed the tendency. MDA level was decreased significantly in HF+MT group compared with that in HF group (17%, 19% in plasma or liver, respectively), whereas SOD activity were increased by about 14%, 12%, in plasma or liver, respectively. These data indicated melatonin treatment could effectively ameliorate antioxidative potency and oxidative stress in the system and liver of HFD rats.
Effects of melatonin on JNK pathway and insulin signaling cascades
We then studied the underlying mechanisms by which melatonin may improve insulin resistance. It is known that oxidative stress can induce various stress-sensitive pathways, including the p38MAPK, ERK, and JNK pathways. One attractive possibility is that oxidative stress-induced insulin resistance is mediated by JNK. This notion is confirmed by previous in vivo study, which demonstrated that inhibition of JNK activity through genetic knock-out or an inhibitor improves insulin sensitivity in mice (20) . As shown in Figure 2 , JNK was activated in HFD rats. In parallel with increased phosphorylation of JNK, phosphorylation of the residue Tyr 612 in IRS2 was decreased. Similarly, activation of JNK led to impaired phosphorylation of PKB. However, these changes of stress-sensitive pathways and insulin signaling cascades were restored by melatonin treatment in HDF rats. The enhanced phosphorylation of JNK in HFD rats was significantly diminished by melatonin treatment (19% less in HF+MT group compared to HF group). Whereas, the reduced phosphorylation of IRS2 and PKB in HFD rats were significantly enhanced by melatonin treatment (25% more and 34% more, respectively, in HF+MT group compared to HF group).
Effects of melatonin on hepatic PEPCK activity and mRNA level
PEPCK is one of the rate-limiting enzymes of gluconeogenesis, which controls the hepatic glucose .daily) treatment prevented the increases significantly (P<0.05, HF+MT vs. HF). The results showed that melatonin could influence gene transcription of hepatic gluconeogenestic enzymes to regulate glucose homeostasis.
Discussion
In the present study, we studied the direct effects of chronic treatment of HFD rats with melatonin at the functional and signaling levels. The major finding was that melatonin treatment markedly improved insulin resistance state and glucose tolerance in HFD rats. This beneficial effect of melatonin was involved, at least in part, in the reduction in oxidative stress and the restoration of insulin signal transduction in the liver.
Epidemiological studies have shown that a HFD promotes the development of obesity and that there is a direct relationship between the amount of dietary fat and the degree of obesity. HFD plays a vital role in the etiology of obesity [21, 22] . In addition, the associations among obesity, insulin resistance, and type 2 diabetes mellitus are well documented [23] [24] [25] [26] . In this study, feeding of HFD to rats induced obesity, as evidenced by increase in BW and higher FW/BW. Related metabolic syndrome such as impaired glucose homeostasis and dyslipdaemia was also observed in HFD rats. It has been identified that increased BW and visceral adiposity are associated with glucose intolerance, insulin resistance, diabetes, dyslipidemia, and cardiovascular disease [27, 28] . These obesity rats possessed typical metabolic characteristics of early insulin resistance, including hyperinsulinemia, higher plasma TG and FFA, impaired glucose tolerance, and normal fasting glucose level. Insulin resistance state in these rats could be further assessed by the parameters of higher HOME-IR and lower ISI. Thus, this model is a successful early insulin resistant rat model and is useful for the study of insulin resistance and insulin sensitivity.
Previous study that indicated melatonin may alter either carbohydrate/lipid metabolism or the ability to store excess energy as body fat. Hanson et.al found that daily melatonin administration to middle-aged male rats suppresses BW, intraabdominal adiposity, and plasma leptin and insulin independent of food intake and total body fat [29] . Melatonin also reduces BW gain in Sprague Dawley rats with diet-induced obesity. Furthermore, in pinealectomized HFD rats, BW gain and feed efficiency were increased 4 wk after surgery. Adipose tissue weight, insulinemia, and glycemia had a tendency to increase. Treatment with melatonin prevented in part these changes [30] . In accordance with these previous observations, our results showed melatonin administration to the HFD rats resulted in a reversed tendency toward BW and intraabdominal adiposity. At 10 th week, BW of the rats administrated with melatonin nearly reached a level comparable to the normal control. Melatonin also counteracted the changes in plasma TG, TC, FFA and HDL-C levels. These data were consistent with the finding [31] , demonstrating that melatonin may act as a regulator of BW and lipid metabolism.
Many studies have shown that melatonin has favorable effects on glucose homeostasis since it might increase glucose tolerance and improve insulin sensitivity in various animal models [32] [33] [34] . Melatonin administration has been shown to acutely decrease plasma insulin level and increase insulin sensitivity in rats [35] . In this study, melatonin administration down-regulated the fasting plasma insulin level and decreased the HOMA index by roughly 10% and 27%, respectively. ISI of HF+MT group was higher than that of HF group. In OGTT, We found that melatonin significantly attenuated the increase in the plasma glucose concentration and improved the insulin response by glucose challenge. These data indicated the We found that one key feature in HFD rats was oxidative stress, as verified by higher MDA level and lower SOD activity in plasma and liver. It is well known that oxidative stress is the potent trigger of insulin resistance in various tissues including muscle, adipose, liver, and endocrine pancreas, etc. [36] [37] [38] . As expected, melatonin as a potent free radical scavenger and antioxidant, efficiently improved the imbalance of reactive oxygen species production and capacity of antioxidant defenses by modulating antioxidant enzymes and/or direct antioxidantive effect in HFD rats. Since melatonin treatment could partially restore redox balance, as evidenced by elevated antioxidative enzyme SOD activity and reduced oxidative marker MDA level in plasma and liver, it is tempting to speculate that the reduction in oxidative stress is a primary factor of ameliorating insulin sensitivity and insulin resistance to varying degrees in HFD rats.
The study also provided insight into the molecular mechanisms by which melatonin improved insulin resistance and glucose homeostasis in HFD fed rats. It is well documented that the activation of multiple serine kinase cascades such as nuclear factor-κB, p38 MAPK, and NH 2 -terminal Jun kinases/stressactivated protein kinases (JNK) is correlated with oxidative stress. These kinases are known to affect the signal transduction of some key components in the insulin signaling pathway, including the insulin receptor substrate (IRS) family of proteins. The increased serine/ threonine phosphorylation of discrete IRS molecular sites in response to the serine kinases activation inversely results in the down-regulation of tyrosine phosphorylated IRS molecules, which are less able to associate with downstream target molecules including protein kinase B (PKB). As a result, insulin signaling is impaired and insulin resistance occurs [39] .
Our results showed that HFD rats manifested oxidative stress in the system and particularly in the liver. Oxidative stress might activate stress-sensitive intracellular signaling pathways, leading to insulin resistance in many tissues such as liver. Indeed, we found the phosphorylation level of JNK was increased, resulting in decreased tyrosine phosphorylation of IRS2, accompanied by decreasing phosphorylation of PKB after insulin injection in HFD rats. Importantly, the oxidative stress-induced activation of JNK pathway and impaired insulin signal transduction were rescued by melatonin treatment. Our results indicated that melatonin reversed the changes of phosphorylation of kinases and/or signaling proteins in various singling cascades particularly in insulin singling pathway, accounting for the improvement of hepatic insulin resistance.
Insulin controls the rate of gluconeogenesis in large by changes in the level of gene transcription and activity of the rate-limiting enzyme (PEPCK) in the liver [40] . Failure of insulin to inhibit hepatic gluconeogenesis is to a large extent responsible for the disruption of glucose homeostasis and development of fasting hyperglycaemia [41] . PKB is a key molecule mediating the metabolic effect of insulin in the liver. It lies downstream of IRS2 and facilitates glycogen synthesis by activating glycogensynthase kinase-3. Also PKB can inhibit gluconeogenesis through direct phosphorylation of various downstream transcription factors and regulation of gene expression [42] . It is reported that activation of PKB in isolated primary hepatocytes decreases PEPCK gene transcription [43] . Our data showed that the PEPCK mRNA level and PEPCK activity in HF group were significantly higher than those in control group. The findings appeared to indicate that in overnight fasting state, HDF rats had higher rate of gluconeogenesis for hepatic glucose output to maintain euglycemia. Previous study indicated that increase in gluconeogenesis is responsible for fasting hyperglycemia [44, 45] . Once this trend continues to develop, hyperglycemia will occur. Similarly, melatonin significantly suppressed the increase in mRNA level of PEPCK and PEPCK activity in the study. Further studies are required to clarify the underlying mechanism. Nevertheless, the results might provide a mechanistic explanation for melatonin inhibiting the excess hepatic glucose product as well as inappropriate glucose homeostasis at this early insulin resistance stage in HFD rats.
In conclusion, our study clearly demonstrates that the anti-oxidative property of melatonin is sufficient to ameliorate insulin resistance condition via suppression of JNK activation and PEPCK expression due to impaired oxidative stress, leading to improved glucose homeostasis and restored hepatic insulin signaling in a rat model of HFD-induced insulin resistance. In addition, our results showed that melatonin inhibited weight gain and intraabdominal adiposity, improving insulin sensitivity, potential of antioxidation, and metabolic profiles. Given that there are multiple actions of melatonin, future clinical trials utilizing melatonin should be encouraged to carry out in the treatment of insulin resistance in obesity-associated type 2 diabetes and other diseases.
